Thrombocytopenia, defined as a platelet count below 150 × 109/L, is a prevalent concern in the intensive care unit (ICU), affecting up to 41% of critically ill patients. The incidence varies significantly across different ICU settings—medical, surgical, cardiac—and among diverse patient demographics due to varying underlying conditions, interventions, and comorbidities. Thrombocytopenia is more than a laboratory anomaly; it is closely associated with adverse outcomes such as increased mortality, heightened bleeding risk, and a greater need for organ support therapies [1, 2] [Ref: Algorithm 92.1].